- Previous Close
14.68 - Open
14.64 - Bid 14.32 x --
- Ask 14.58 x --
- Day's Range
14.00 - 14.64 - 52 Week Range
9.18 - 24.00 - Volume
2,011 - Avg. Volume
17,454 - Market Cap (intraday)
494.114M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-5.89 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.50
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
www.orexo.com110
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ORX.ST
View MorePerformance Overview: ORX.ST
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORX.ST
View MoreValuation Measures
Market Cap
506.54M
Enterprise Value
859.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.86
Price/Book (mrq)
--
Enterprise Value/Revenue
1.46
Enterprise Value/EBITDA
17.57
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.41%
Return on Assets (ttm)
-13.22%
Return on Equity (ttm)
--
Revenue (ttm)
590M
Net Income Avi to Common (ttm)
-203M
Diluted EPS (ttm)
-5.89
Balance Sheet and Cash Flow
Total Cash (mrq)
123.3M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
5.01M